HIV RNA levels in plasma and cervical-vaginal lavage fluid in elite controllers and HAART recipients

AIDS

Volumn 28, Issue 5, 2014, Pages 739-743

  Landay, Alan ^a   Golub, Elizabeth T ^b   Desai, Seema ^a   Zhang, Jinbing ^b   Winkelman, Val ^c   Anastos, Kathryn ^d   Durkin, Helen ^e   Young, Mary ^f   Villacres, Maria C ^g   Greenblatt, Ruth M ^h   Norris, Philip J ⁱ   Busch, Michael P ⁱ  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CREATIVE TESTING SOLUTIONS   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical vaginal lavage; Elite controllers; HAART suppressed patients; TMA

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA; ANTIRETROVIRUS AGENT;

ARTICLE; BLOOD LEVEL; CERVICAL VAGINAL LAVAGE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; UTERINE CERVIX CYTOLOGY; VAGINAL LAVAGE; VIREMIA; VIRUS CONCENTRATION; VIRUS LOAD; VIRUS REPLICATION; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ISOLATION AND PURIFICATION; PLASMA; VAGINA; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; PLASMA; RNA, VIRAL; VAGINA; VAGINAL DOUCHING; VIRAL LOAD;

EID: 84898011439     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000150     Document Type: Article

References (17)

1. Pallela FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
3. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697-706.
4. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338:a3172.
5. Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007; 27:406-416.
6. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, et al. Persistent low-level viremia in HIV-1 'elite controllers' and relationship to immunologic parameters. J infect Dis 2009; 200:984-990.
7. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947.
8. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133.
9. Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis 2008; 47:102-104.
10. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 2009; 83:329-335.
11. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The Women's Interagency HIV study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-1019.
12. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish L, Miotti P, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. Epidemiology 1998; 9:117-125.
13. Busch MP, Hecht FM. Nucleic acid amplification testing for diagnosis of acute HIV infection: has the time come? AIDS 2005; 19:1317-1319.
14. Hughes MD. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Stat Med 2000; 19:3171-3191.
15. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 2011; 6:e15924.
16. Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. Plos Pathog 2013; 9:e1003691.
17. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.